Aristo Pharma Nordic ApS: Financial statements 2012
CVR: 32328768
Source: annual report 2012, Danish Business Authority
01/10/2011 – 30/09/2012
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -297,210 and a net result of DKK -428,002. Equity in the 2012 report amounted to DKK -484,263.
- Gross Profit
- DKK -297,210
- Profit/Loss
- DKK -428,002
- Equity
- DKK -484,263
- Total Assets
- DKK 1,516,081
Official annual report
Keep an eye on Aristo Pharma Nordic ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of May 1, 2012, John Morell Frellsen is registered as director of Aristo Pharma Nordic ApS.
As of May 1, 2012, Peter Lassen has stepped down as director of Aristo Pharma Nordic ApS.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.